Nabla Bio Secures $26M in Series A Funding to Accelerate Drug Discovery Revolution

Nabla Bio, a pioneering biotech firm revolutionizing drug development through the integration of artificial intelligence and cutting-edge wet-lab technologies, is thrilled to announce that it has raised $26 million in its latest funding round. This impressive amount contributes to the company’s total funding to date of $37 million, with support from prominent investors such as Radical Ventures, Khosla Ventures, and Zetta Venture Partners. The newly acquired capital will be strategically directed towards enhancing Nabla Bio's innovative platform, which is designed to facilitate the rational design of selective, functional drugs targeting previously undruggable diseases. By collaborating with leading pharmaceutical giants, including AstraZeneca, Bristol Myers Squibb, and Takeda, Nabla aims to enrich their pipelines with high-quality drug candidates, ultimately working towards doubling the number of viable drug targets that can be advanced to the development stage. Since its inception in 2021, Nabla Bio has established itself as a vital player in the biotech landscape, and this latest funding round underscores increasing investor confidence in its mission to transform the future of medicine. Furthermore, with a technical team based in the innovation hub of Cambridge, Massachusetts, Nabla Bio is actively looking to recruit top-tier talent in machine learning and synthetic biology to bolster its capabilities. Interested candidates are encouraged to explore opportunities in the Careers section of their website at www.nabla.bio. With this funding, Nabla Bio is poised to accelerate its growth and enhance patient outcomes in the pharmaceutical industry.